Procept Biorobotics Corp Stock Price, News & Analysis

PROCEPT BioRobotics plans to report its fourth quarter and fiscal year 2022 financial results on February 28, 2023. Preliminary unaudited revenue for Q4 2022 is projected between $23.6 million and $23.8 million, significantly up from $10.1 million in Q4 2021. Total revenue for fiscal year 2022 is expected to be around $74.8 million to $75 million, reflecting a 117% growth year-over-year. The company emphasizes its commitment to advancing patient care in urology through innovative surgical solutions.

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference, scheduled for January 10, 2023, at 9:45 a.m. Pacific Time. The event will feature a presentation by the company's management team. Interested parties can access a live webcast and an archived recording through the company’s website.

PROCEPT BioRobotics focuses on innovating surgical robotics for urology, specifically addressing benign prostatic hyperplasia (BPH) through its AquaBeam Robotic System, which is backed by extensive clinical evidence.

PROCEPT BioRobotics (Nasdaq: PRCT) reported a 135% increase in total revenue for Q3 2022, totaling $20.3 million compared to the same period last year. U.S. system revenue rose 95% to $9.8 million, while handpiece revenue surged 267% to $8.0 million. The company raised its 2022 revenue guidance to approximately $72.5 million, a 110% growth over 2021. However, net loss widened to $22.6 million and operating expenses increased to $32.3 million.

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) will release its third quarter financial results on November 3, 2022, after the market closes. A conference call with management will follow at 1:30 p.m. Pacific Time. Investors can join via webcast or phone. The company is focused on surgical robotics, specifically addressing benign prostatic hyperplasia (BPH) through the AquaBeam Robotic System, which has shown significant clinical evidence in improving patient outcomes. Information on the event will be accessible on their website and archived recordings will be available for 90 days.

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) announced a new five-year $52 million loan agreement with CIBC Innovation Banking to enhance its financial position. This loan will refinance an existing $50 million debt, allowing for an interest-only payment period of up to 48 months and reducing annual interest expenses by approximately $2.8 million. CFO Kevin Waters emphasized that this arrangement supports the company’s long-term growth strategy and provides financial flexibility. PROCEPT specializes in surgical robotics, focusing on treating benign prostatic hyperplasia.

PROCEPT BioRobotics (Nasdaq: PRCT) and Providence have formed a multi-system national contract for the acquisition of AquaBeam Robotic Systems, enhancing patient care in urology. As of June 30, 2022, Providence had seven AquaBeam systems installed in California and Texas. Doctor Richard Shapiro emphasized that Aquablation therapy offers long-term symptom relief for men with benign prostatic hyperplasia. PROCEPT aims to accelerate adoption of Aquablation therapy, prioritizing patient safety and effectiveness by using advanced robotic technology for precise prostate treatment.

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) has announced its participation in the 2022 Wells Fargo healthcare conference, with management scheduled to present on September 7 at 9:10 a.m. Eastern Time. The event will be available via live webcast on the company’s website, offering an archived recording for at least 90 days post-event. PROCEPT focuses on advancing patient care through innovative surgical robotics, particularly with its AquaBeam Robotic System aimed at treating benign prostatic hyperplasia, impacting about 40 million men in the U.S.

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) reported Q2 2022 results showing a 97% year-over-year revenue increase to $16.7 million, driven by strong U.S. sales. System revenue reached $8.5 million (+79%), while handpiece sales surged 246% to $5.7 million. The company raised its 2022 revenue guidance to $66-$68 million (91%-97% growth). However, net loss grew to $19.2 million from $14.6 million in the prior year. Operating expenses increased to $26.4 million, reflecting expansion efforts. Cash reserves stand at $269.8 million.

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) announced it will release its financial results for the second quarter of 2022 on August 4, 2022, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET. Investors can listen through a webcast or by registering for a call. PROCEPT focuses on surgical robotics and advanced solutions in urology, particularly for treating benign prostatic hyperplasia (BPH). The company highlights its AquaBeam Robotic System and significant clinical evidence supporting its Aquablation therapy.